167 related articles for article (PubMed ID: 16467116)
1. Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations.
Gururaj AE; Rayala SK; Vadlamudi RK; Kumar R
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1001s-1007s. PubMed ID: 16467116
[TBL] [Abstract][Full Text] [Related]
2. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.
Arpino G; Wiechmann L; Osborne CK; Schiff R
Endocr Rev; 2008 Apr; 29(2):217-33. PubMed ID: 18216219
[TBL] [Abstract][Full Text] [Related]
3. Deciphering Steroid Receptor Crosstalk in Hormone-Driven Cancers.
Truong TH; Lange CA
Endocrinology; 2018 Dec; 159(12):3897-3907. PubMed ID: 30307542
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of endocrine resistance in breast cancer.
Osborne CK; Schiff R
Annu Rev Med; 2011; 62():233-47. PubMed ID: 20887199
[TBL] [Abstract][Full Text] [Related]
5. Targeting systemic and gut microbial metabolism in ER
Heath H; Mogol AN; Santaliz Casiano A; Zuo Q; Madak-Erdogan Z
Trends Endocrinol Metab; 2024 Apr; 35(4):321-330. PubMed ID: 38220576
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial estrogen receptors alter mitochondrial priming and response to endocrine therapy in breast cancer cells.
Karakas B; Aka Y; Giray A; Temel SG; Acikbas U; Basaga H; Gul O; Kutuk O
Cell Death Discov; 2021 Jul; 7(1):189. PubMed ID: 34294688
[TBL] [Abstract][Full Text] [Related]
7. Biological determinants of endocrine resistance in breast cancer.
Musgrove EA; Sutherland RL
Nat Rev Cancer; 2009 Sep; 9(9):631-43. PubMed ID: 19701242
[TBL] [Abstract][Full Text] [Related]
8. Modeling breast cancer proliferation, drug synergies, and alternating therapies.
He W; Demas DM; Shajahan-Haq AN; Baumann WT
iScience; 2023 May; 26(5):106714. PubMed ID: 37234088
[TBL] [Abstract][Full Text] [Related]
9. Overview of the therapeutic strategies for ER positive breast cancer.
Blakely B; Shin S; Jin K
Biochem Pharmacol; 2023 Jun; 212():115552. PubMed ID: 37068524
[TBL] [Abstract][Full Text] [Related]
10. Exploring new pathways in endocrine-resistant breast cancer.
de Pinho IS; Abreu C; Gomes I; Casimiro S; Pacheco TR; de Sousa RT; Costa L
Explor Target Antitumor Ther; 2022; 3(3):337-361. PubMed ID: 36045911
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Vps34 and p110δ PI3K Impairs Migration, Invasion and Three-Dimensional Spheroid Growth in Breast Cancer Cells.
Di Donato M; Giovannelli P; Migliaccio A; Bilancio A
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012280
[TBL] [Abstract][Full Text] [Related]
12. Dysregulation of DNA methylation patterns may identify patients with breast cancer resistant to endocrine therapy: A predictive classifier based on differentially methylated regions.
Zhang F; Cui Y
Oncol Lett; 2019 Aug; 18(2):1287-1303. PubMed ID: 31423189
[TBL] [Abstract][Full Text] [Related]
13. Gene Expression Assays for Early-Stage Hormone Receptor-Positive Breast Cancer: Understanding the Differences.
Nunes AT; Collyar DE; Harris LN
JNCI Cancer Spectr; 2017 Sep; 1(1):pkx008. PubMed ID: 31360834
[TBL] [Abstract][Full Text] [Related]
14. The potential influence of breast cancer estrogen receptors' distribution on active DNA demethylation.
Linowiecka K; Urbanowska-Domańska O; Guz J; Foksiński M
Contemp Oncol (Pozn); 2019; 23(2):74-80. PubMed ID: 31316288
[TBL] [Abstract][Full Text] [Related]
15. L-Thyroxine induces thermotolerance in yeast.
Papamichael K; Delitheos B; Mourouzis I; Pantos C; Tiligada E
Cell Stress Chaperones; 2019 Mar; 24(2):469-473. PubMed ID: 30737613
[TBL] [Abstract][Full Text] [Related]
16. Nodes-and-connections RNAi knockdown screening: identification of a signaling molecule network involved in fulvestrant action and breast cancer prognosis.
Miyoshi N; Wittner BS; Shioda K; Hitora T; Ito T; Ramaswamy S; Isselbacher KJ; Sgroi DC; Shioda T
Oncogenesis; 2015 Oct; 4(10):e172. PubMed ID: 26479444
[TBL] [Abstract][Full Text] [Related]
17. Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor-positive breast cancers.
Ribas R; Ghazoui Z; Gao Q; Pancholi S; Rani A; Dunbier A; Dowsett M; Martin LA
Breast Cancer Res; 2014 Oct; 16(5):447. PubMed ID: 25358600
[TBL] [Abstract][Full Text] [Related]
18. Critical roles for nitric oxide and ERK in the completion of prosurvival autophagy in 4OHTAM-treated estrogen receptor-positive breast cancer cells.
Duan L; Danzer B; Levenson VV; Maki CG
Cancer Lett; 2014 Oct; 353(2):290-300. PubMed ID: 25069039
[TBL] [Abstract][Full Text] [Related]
19. Drug resistance to targeted therapies: déjà vu all over again.
Groenendijk FH; Bernards R
Mol Oncol; 2014 Sep; 8(6):1067-83. PubMed ID: 24910388
[TBL] [Abstract][Full Text] [Related]
20. Exosome-bound WD repeat protein Monad inhibits breast cancer cell invasion by degrading amphiregulin mRNA.
Saeki M; Egusa H; Kamano Y; Kakihara Y; Houry WA; Yatani H; Noguchi S; Kamisaki Y
PLoS One; 2013; 8(7):e67326. PubMed ID: 23844004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
